Quick Answer
ALNYLAM PHARMACEUTICALS, INC. reported Operating Income of $501.58 million for fiscal year 2025.
ALNYLAM PHARMACEUTICALS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $501.58M | +383.6% |
| 2024 | -$176.88M | +37.3% |
| 2023 | -$282.18M | +64.1% |
| 2022 | -$785.07M | -10.8% |
| 2021 | -$708.65M | +14.5% |
| 2020 | -$828.44M | +11.8% |
| 2019 | -$939.43M | -15.3% |
| 2018 | -$814.67M | -62.9% |
| 2017 | -$500.09M | -17.8% |
| 2016 | -$424.59M | -43.4% |
| 2015 | -$296.01M | +26.9% |
| 2014 | -$404.98M | -335.7% |
| 2013 | -$92.94M | +28.2% |
| 2012 | -$129.46M | -136.2% |
| 2011 | -$54.82M | -24.4% |
| 2010 | -$44.07M | +8.4% |
| 2009 | -$48.11M | -72.8% |
| 2008 | -$27.84M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $367.98M | +578.5% | +2371.6% |
| June 30, 2025 | -$16.20M | -133.3% | -189.6% |
| March 31, 2025 | $18.08M | +141.6% | +123.5% |
| September 30, 2024 | -$76.91M | -136.0% | -258.2% |
| June 30, 2024 | $48.61M | +121.2% | +211.9% |
| March 31, 2024 | -$43.44M | +71.0% | -120.3% |
| September 30, 2023 | $213.87M | +182.9% | +193.1% |
| June 30, 2023 | -$229.83M | -19.9% | -53.4% |
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +383.6% in Operating Income compared to the prior fiscal year.
- Over the 2008–2025 period, ALNYLAM PHARMACEUTICALS, INC.’s operating income has grown by 1902.0% (from -$27.84 million to $501.58 million).
- The most recent figure is from ALNYLAM PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: